Gene Therapy

Inomagen’s gene therapy program has demonstrated preclinical success targeting underlying mechanisms of AF, and has advanced into IND-enabling studies with an independent CRO.

Inomagen is developing a biological (gene) therapy with improved efficacy for AF patients including undertreated patients with advanced stage (persistent) AF.

We have

  • Identified major molecular mechanisms that contribute to AF in a majority of patients with AF

  • Identified major trans-genes to selectively target these mechanisms in the atrium

  • Utilized electroporation following gene injection to provide therapeutic gene transfer and expression

  • Decreased AF in clinically relevant, large animal models of AF

  • Advanced the program into IND-enabling studies with an independent CRO

Targeting underlying molecular mechanisms of AF

Inomagen’s gene therapy has demonstrated preclinical success in large animal models of AF

Preventing Electrical Remodeling – Inomagen’s Gene Therapy (NOX2 shRNA) prevented the onset of AF in both a short and long-term rapid atrial pacing (RAP) model

Minimizing Structural Remodeling – Inomagen’s Gene Therapy (NOX2 shRNA) Dramatically Reduced AF Induced Fibrosis

Future Targets – Inomagen has identified other promising proprietary targets for future development (e.g., NGF shRNA targets autonomic nervous system)